<DOC>
	<DOC>NCT01988493</DOC>
	<brief_summary>This is an open-label, integrated, Phase 1b/2 trial to determine the recommended Phase 2 dose (RP2D) and to evaluate the efficacy, safety, and pharmacokinetic of MSC2156119J as first-line treatment versus sorafenib in subjects with MET+, Barcelona Clinic Liver Cancer (BCLC) Stage C, systemic treatment naive advanced hepatocellular carcinoma (HCC) and Child-Pugh class A liver function.</brief_summary>
	<brief_title>Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Subjects With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically or cytologically confirmed HCC Subjects with advanced HCC of BCLC Stage C Subjects who have disease progression on or are intolerant to the prior standard treatment for advanced HCC (phase Ib Korean subjects only) A tumor biopsy is required for determining MET status MET+ status (Phase 2 only), as determined by the central laboratory (Phase 1b retrospectively, Phase 2 for subject selection) as defined in the protocol ChildPugh class A with no encephalopathy according to the screening assessment Asian male or female, 18 years of age or older Measurable disease in accordance with RECIST v1.1 (Phase 2 only) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 Eligible for treatment with sorafenib, as assessed by investigators according to the Package Insert and clinical judgment (Phase 2 only) Signed and dated informed consent indicating that the subject has been informed of all the pertinent aspects of the trial prior to enrollment Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures Life expectancy judged by the investigator of at least 3 months Prior systemic anticancer treatment for advanced HCC, including targeted therapy (for example, sorafenib), chemotherapy, or any other investigational agent (Phase 2 only) Prior treatment with any agent targeting the hepatocyte growth factor (HGF)/cMet pathway Prior localregional therapy within 4 weeks prior to Day 1 of trial treatment Prior history of liver transplant Laboratory index at baseline as defined in the protocol Past or current history of neoplasm other than HCC, except for curatively treated nonmelanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least 5 years Known central nervous system (CNS) or brain metastasis that is either symptomatic or untreated Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested products Clinically significant gastrointestinal bleeding within 4 weeks before trial entry Peripheral neuropathy Grade greater than or equal to 2 (Common Terminology Criteria for Adverse Events [CTCAE] v4.0) Impaired cardiac function as defined in the protocol Hypertension uncontrolled by standard therapies Subject with a family history of long QT syndrome or who take any agent that is known to prolong QT/QTc interval Known human immunodeficiency virus (HIV) infection Subjects who have acute pancreatitis and/or chronic pancreatitis, with elevated lipase and/or amylase, clinical symptoms, and/or imaging studies that are indicative of the diagnosis (Mainland Chinese subjects only) Known or suspected drug hypersensitivity to any ingredients of sorafenib (Phase 2 only) and MSC2156119J Female subjects who are pregnant or lactating, or males and females of reproductive potential not willing or not able to employ a highly effective method of birth control/contraception to prevent pregnancy from 2 weeks before receiving study drug until 3 months after receiving the last dose of study drug Concurrent treatment with a nonpermitted drug Substance abuse, other acute or chronic medical or psychiatric condition, or laboratory abnormalities that may increase the risk associated with trial participation in the opinion of the investigator Participation in another clinical trial within the past 28 days Previous anticancer treatmentrelated toxicities not recovered to baseline or Grade 01 (except alopecia and peripheral neuropathy) Subjects with any concurrent medical condition or disease that will potentially compromise the conduction of the study at the discretion of the investigators</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Carcinoma, Hepatocellular</keyword>
	<keyword>MSC2156119J</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Recommended Phase 2 dose</keyword>
</DOC>